Hutchmed (HCM) announces that the New Drug Application for Tazverik has been granted conditional approval in China for the treatment of adult patients with relapsed or refractory follicular lymphoma with EZH2 mutation who have received at least two prior systemic therapies. This approval follows the priority review status by the National Medical Products Administration and marks the first nationwide regulatory approval for Tazverik in China.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCM:
- HUTCHMED’s Strong Financial Performance and Strategic Growth Drive Buy Rating
- Hutchmed Reports Strong 2024 Growth and Profitability
- Hutchmed sees FY25 Oncology/Immunology revenue $350M-$450M
- Hutchmed reports FY24 EPS 22c vs. 59c last year
- Hutchmed/Innovent update on Phase 2/3 study of Fruquintinib+Sintilimab
Questions or Comments about the article? Write to editor@tipranks.com